Roquefort Therapeutics (LON:ROQ) Shares Down 3.3% – Time to Sell?

Roquefort Therapeutics plc (LON:ROQ)’s share price traded down 3.3% on Tuesday . The company traded as low as GBX 4.10 ($0.05) and last traded at GBX 4.35 ($0.05). 761,441 shares traded hands during mid-day trading, an increase of 27% from the average session volume of 600,833 shares. The stock had previously closed at GBX 4.50 ($0.06).

Roquefort Therapeutics Price Performance

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock has a market capitalization of £4.94 million, a price-to-earnings ratio of -382.40 and a beta of 0.05. The stock has a 50-day moving average price of GBX 4.28 and a 200 day moving average price of GBX 4.19.

About Roquefort Therapeutics

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.